keyword
MENU ▼
Read by QxMD icon Read
search

Taxotere

keyword
https://www.readbyqxmd.com/read/28314341/navelbine%C3%A2-and-taxot%C3%A3-re%C3%A2-1st-edition
#1
(no author information available yet)
No abstract text is available yet for this article.
March 2017: Anticancer Research
https://www.readbyqxmd.com/read/28165821/successful-delivery-of-docetaxel-to-rat-brain-using-experimentally-developed-nanoliposome-a-treatment-strategy-for-brain-tumor
#2
Tapan Kumar Shaw, Dipika Mandal, Goutam Dey, Murari Mohan Pal, Paramita Paul, Samrat Chakraborty, Kazi Asraf Ali, Biswajit Mukherjee, Amal Kumar Bandyopadhyay, Mahitosh Mandal
Docetaxel (DTX) is found to be very effective against glioma cell in vitro. However, in vivo passage of DTX through BBB is extremely difficult due to the physicochemical and pharmacological characteristics of the drug. No existing formulation is successful in this aspect. Hence, in this study, effort was made to send DTX through blood-brain barrier (BBB) to brain to treat diseases such as solid tumor of brain (glioma) by developing DTX-loaded nanoliposomes. Primarily drug-excipients interaction was evaluated by FTIR spectroscopy...
November 2017: Drug Delivery
https://www.readbyqxmd.com/read/28017889/blood-brain-barrier-penetrating-amphiphilic-polymer-nanoparticles-deliver-docetaxel-for-the-treatment-of-brain-metastases-of-triple-negative-breast-cancer
#3
Chunsheng He, Ping Cai, Jason Li, Tian Zhang, Lucy Lin, Azhar Z Abbasi, Jeffrey T Henderson, Andrew Michael Rauth, Xiao Yu Wu
Brain metastasis is a fatal disease with limited treatment options and very short survival. Although systemic chemotherapy has some effect on peripheral metastases of breast cancer, it is ineffective in treating brain metastasis due largely to the blood-brain barrier (BBB). Here we developed a BBB-penetrating amphiphilic polymer-lipid nanoparticle (NP) system that efficiently delivered anti-mitotic drug docetaxel (DTX) for the treatment of brain metastasis of triple negative breast cancer (TNBC). We evaluated the biodistribution, brain accumulation, pharmacokinetics and efficacy of DTX-NP in a mouse model of brain metastasis of TNBC...
December 23, 2016: Journal of Controlled Release: Official Journal of the Controlled Release Society
https://www.readbyqxmd.com/read/27997900/a-difference-in-the-incidences-of-hypersensitivity-reactions-to-original-and-generic-taxanes
#4
Tanchanok Ratanajarusiri, Virote Sriuranpong, Piyada Sitthideatphaiboon, Nattaya Poovoravan, Chanida Vinayanuwat, Napa Parinyanitikul, Pattama Angspatt, Wilai Thawinwisan, Suebpong Tanasanvimon
PURPOSE: To compare incidences of hypersensitivity reaction (HSR) between original and generic taxanes including paclitaxel and docetaxel. METHODS: We conducted a prospective study enrolling all patients receiving taxanes at King Chulalongkorn Memorial Hospital. Taxanes were infused accordingly to the step-wise rate escalation protocol at this hospital. Active surveillance for HSRs was performed. During the study period, there was only 1 generic brand used for each taxane...
2017: Chemotherapy
https://www.readbyqxmd.com/read/27991616/atb-0-transporter-mediated-targeting-delivery-to-human-lung-cancer-cells-via-aspartate-modified-docetaxel-loading-stealth-liposomes
#5
Qiuhua Luo, Bin Yang, Wenhui Tao, Jia Li, Longfa Kou, He Lian, Xin Che, Zhonggui He, Jin Sun
Tumor cells have an increased demand for amino acids to support their rapid growth and malignant metastasis. Transfer of amino acids across plasma membranes depends on several amino acid transporters that are highly upregulated in tumor cells and are promising targets for tumor cell-selective therapy. In this study, stealth liposomal systems functionalized with aspartate-polyoxyethylene stearate conjugate (APS) were developed for transporter-mediated targeted delivery to ATB(0,+), which is overexpressed human lung cells...
December 19, 2016: Biomaterials Science
https://www.readbyqxmd.com/read/27981366/a-prospective-exploration-of-symptom-burden-clusters-in-women-with-breast-cancer-during-chemotherapy-treatment
#6
Maria Browall, Yvonne Brandberg, Salmir Nasic, Per Rydberg, Jonas Bergh, Andreas Rydén, Hanjing Xie, Irene Eriksson, Yvonne Wengström
PURPOSE: The aim was to prospectively map symptom clusters in patients with stage I-IIIa breast cancer during standard chemotherapy treatment in a randomised study. METHODS: Participants completed the Memorial Symptom Assessment Scale (MSAS) at baseline, day 12 after the first and third cycle of FEC 75 or FEC 100, and day 12 after the last cycle of Taxotere. Cut-off values for symptom scores, a mean value based on each individual reporting a symptom including occurrence, frequency, severity and distress for inclusion in analysis, were determined...
December 15, 2016: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/27968861/effects-of-induction-taxotere-platinum-and-fluorouracil-tpf-chemotherapy-in-patients-with-stage-iii-and-iva-b-nasopharyngeal-cancer-treated-with-concurrent-chemoradiation-therapy-final-results-of-two-parallel-phase-2-clinical-trials
#7
Lin Kong, Youwang Zhang, Chaosu Hu, Ye Guo, Jiade J Lu
BACKGROUND: Concurrent chemoradiotherapy (CCRT) is the standard treatment for locally advanced nasopharyngeal cancer. The effect of induction chemotherapy plus CCRT in patients with this stage of disease is unclear. We therefore examined the long-term outcomes of the addition of induction chemotherapy (consisting of docetaxel, cisplatin, and fluorouracil [TPF]) to CCRT in patients with stage III and IVA/B nasopharyngeal cancer. METHODS: Between January, 2007, and July, 2011, we synchronously undertook two parallel phase 2 single-arm trials to evaluate the efficacy and toxicity of TPF-based induction chemotherapy...
October 2016: Lancet
https://www.readbyqxmd.com/read/27966988/docetaxel-loaded-plga-nanoparticles-improve-efficacy-in-taxane-resistant-triple-negative-breast-cancer
#8
Charles J Bowerman, James D Byrne, Kevin S Chu, Allison N Schorzman, Amanda W Keeler, Candice A Sherwood, Jillian L Perry, James C Luft, David B Darr, Allison M Deal, Mary E Napier, William C Zamboni, Norman E Sharpless, Charles M Perou, Joseph M DeSimone
Novel treatment strategies, including nanomedicine, are needed for improving management of triple-negative breast cancer. Patients with triple-negative breast cancer, when considered as a group, have a worse outcome after chemotherapy than patients with breast cancers of other subtypes, a finding that reflects the intrinsically adverse prognosis associated with the disease. The aim of this study was to improve the efficacy of docetaxel by incorporation into a novel nanoparticle platform for the treatment of taxane-resistant triple-negative breast cancer...
January 11, 2017: Nano Letters
https://www.readbyqxmd.com/read/27873118/current-update-of-a-carboxymethylcellulose-peg-conjugate-platform-for-delivery-of-insoluble-cytotoxic-agents-to-tumors
#9
Yang Yang, Joseph Bteich, Shyh-Dar Li
Cytotoxic chemotherapeutic agents are used as the standard therapy for a range of significant cancers, but many of these drugs suffer from poor water solubility and low selectivity, limiting their clinical efficacy. To overcome these shortcomings, Cellax™ drug delivery platform was developed. Cellax™ is a polymer-based nanoparticle drug delivery system designed to solubilize hydrophobic drugs and target them to solid tumors, thereby enhancing the efficacy and reducing the side effects. Cellax-docetaxel (Cellax-DTX) displayed improved pharmacokinetic, safety, and efficacy profiles compared to native DTX (Taxotere®) and Nab-paclitaxel (Nab-PTX, Abraxane®) in multiple animal models...
March 2017: AAPS Journal
https://www.readbyqxmd.com/read/27861147/arctigenin-inhibits-stat3-and-exhibits-anticancer-potential-in-human-triple-negative-breast-cancer-therapy
#10
Tingting Feng, Wei Cao, Wanxiang Shen, Liang Zhang, Xinsheng Gu, Yang Guo, Hsiang-I Tsai, Xuewen Liu, Jian Li, Jingxuan Zhang, Shan Li, Fuyun Wu, Ying Liu
Triple-negative breast cancers (TNBCs) are the most aggressive and hard-to-treat breast tumors with poor prognosis, and exploration for novel therapeutic drugs is impending. Arctigenin (Atn), a bioactive lignan isolated from seeds of Arctium lappa L, has been reported to inhibit many cancer types; however, the effect of Atn on TNBC remains unclear. In this study, we demonstrated that Atn decreased proliferation, and induced apoptosis in TNBC cells. Furthermore, we explored the underlying mechanism of Atn inhibition on TNBC cells...
January 3, 2017: Oncotarget
https://www.readbyqxmd.com/read/27675824/the-effects-of-induction-taxotere-platinum-and-fluorouracil-tpf-chemotherapy-in-patients-with-stage-iii-and-iva-b-nasopharyngeal-cancer-treated-with-concurrent-chemoradiation-therapy-long-term-results-of-2-parallel-phase-2-clinical-trials
#11
L Kong, C Hu, Y Guo, Y Zhang, J J Lu
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27644657/phase-ii-study-of-compliance-and-morbidity-with-4-cycles-of-taxotere-followed-by-4-of-doxorubicin-cyclophosphamide-for-adjuvant-treatment-of-operable-breast-cancer-patients
#12
Rami Jalal Yaghan, Nawaf Mahmood Dagher
BACKGROUND: In the adjuvant treatment of breast cancer, anthracycline and taxane based regimens can be used concomitantly or sequentially. The best order in the sequential regimens has yet to be well established. This study evaluated the feasibility of 4 cycles of adjuvant taxotere (100mg/m2) every 3 weeks followed by 4 cycles of doxorubicin (60 mg/m2) and cyclophosphamide (600mg/m2) every 3 weeks. The primary outcome was the safety profile. Secondary outcomes were disease free survival (DFS) and overall survival (OS)...
2016: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/27479828/comparing-the-incidence-of-febrile-neutropenia-resulting-in-hospital-admission-between-the-branded-docetaxel-and-the-generic-formulations
#13
Nour Al Faqeer, Ola Mashni, Rawan Dawoud, Asma Rumman, Esraa Hanoun, Lama Nazer
Studies have raised concern about the safety of generic compared with branded drugs. Febrile neutropenia (FN) resulting in hospital admission was compared between the branded docetaxel (Taxotere®, Sanofi) and 2 generic formulations (docetaxel Ebewe and docetaxel Hospira) in patients with breast cancer. This was a retrospective study that included patients with breast cancer who received docetaxel between January 2012 and December 2014. Patients who had an admission diagnosis of FN and had received docetaxel within 14 days prior to admission were evaluated...
February 2017: Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/27476608/docetaxel-loaded-polyglutamic-acid-peg-nanocapsules-for-the-treatment-of-metastatic-cancer
#14
Erea Borrajo, Raquel Abellan-Pose, Atenea Soto, Marcos Garcia-Fuentes, Noemi Csaba, Maria J Alonso, Anxo Vidal
The design of nanomedicines with suitable physicochemical characteristics for the lymphatic targeting of drugs is critical in order to reach the lymph nodes, where metastatic cells often accumulate. Based on the known effect of particle size and surface hydrophilicity on the capacity of nanocarriers to reach the lymph nodes, here we report the formation and characterization of 100nm polyglutamic acid-polyethylene glycol (PGA-PEG) nanocapsules together with the assessment of their potential for the treatment of cancer with lymphatic metastatic spread...
September 28, 2016: Journal of Controlled Release: Official Journal of the Controlled Release Society
https://www.readbyqxmd.com/read/27447971/serotonin-transporter-antagonists-target-tumor-initiating-cells-in-a-transgenic-mouse-model-of-breast-cancer
#15
Robin M Hallett, Adele Girgis-Gabardo, William D Gwynne, Andrew O Giacomelli, Jennifer N P Bisson, Jeremy E Jensen, Anna Dvorkin-Gheva, John A Hassell
Accumulating data suggests that the initiation and progression of human breast tumors is fueled by a rare subpopulation of tumor cells, termed breast tumor-initiating cells (BTIC), which resist radiotherapy and chemotherapy. Consequently, therapies that abrogate BTIC activity are needed to achieve durable cures for breast cancer patients. To identify such therapies we used a sensitive assay to complete a high-throughput screen of small molecules, including approved drugs, with BTIC-rich mouse mammary tumor cell populations...
August 16, 2016: Oncotarget
https://www.readbyqxmd.com/read/27354816/comparison-of-the-effectiveness-and-toxicity-of-neoadjuvant-chemotherapy-regimens-capecitabine-epirubicin-cyclophosphamide-vs-5-fluorouracil-epirubicin-cyclophosphamide-followed-by-adjuvant-capecitabine-docetaxel-vs-docetaxel-in-patients-with-operable-breast
#16
Minmin Zhang, Wei Wei, Jianlun Liu, Huawei Yang, Yi Jiang, Wei Tang, Qiuyun Li, Xiaoming Liao
The aim of this study was to compare the effectiveness and toxicity of neoadjuvant chemotherapy regimens, xeloda/epirubicin/cyclophosphamide (XEC) vs 5-fluorouracil/epirubicin/cyclophosphamide (FEC), followed by adjuvant chemotherapy regimens, capecitabine/taxotere (XT) vs taxotere (T), in axillary lymph node (LN)-positive early-stage breast cancer. In this randomized, Phase III trial, 137 patients with operable primary breast cancer (T2-0, N0-1) who were tested axillary LN positive through aspiration biopsy of axillary LNs were randomized (1:1) to four 3-weekly cycles of XEC or FEC...
2016: OncoTargets and Therapy
https://www.readbyqxmd.com/read/27241877/formulation-optimization-of-docetaxel-loaded-self-emulsifying-drug-delivery-system-to-enhance-bioavailability-and-anti-tumor-activity
#17
Guru R Valicherla, Kandarp M Dave, Anees A Syed, Mohammed Riyazuddin, Anand P Gupta, Akhilesh Singh, Wahajuddin, Kalyan Mitra, Dipak Datta, Jiaur R Gayen
Poor bioavailability of Docetaxel (DCT) arising due to its low aqueous solubility and permeability limits its clinical utility. The aim of the present study was to develop DCT loaded self-emulsified drug delivery systems (D-SEDDS) and evaluate its potential ability to improve the oral bioavailability and therapeutic efficacy of DCT. D-SEDDS were characterized for their in vitro antitumor activity, in situ single pass intestinal perfusion (SPIP), bioavailability, chylomicron flow blocking study and bio-distribution profile...
2016: Scientific Reports
https://www.readbyqxmd.com/read/27122375/the-role-of-angiogenesis-in-the-persistence-of-chemoresistance-in-epithelial-ovarian-cancer
#18
Osama Nusrat, Jimmy Belotte, Nicole M Fletcher, Ira Memaj, Mohammed G Saed, Michael P Diamond, Ghassan M Saed
OBJECTIVE: Chemoresistance remains a major challenge in the treatment of ovarian cancer. As part of a survival mechanism, tumor cells have been shown to release proangiogenic factors, such as vascular endothelial growth factor (VEGF), through a mechanism that involves the upregulation of hypoxia-induced factor (HIF)-1α. The objective of this study was to compare the expression of VEGF and its receptors (R1 and R2) as well as HIF-1α in chemoresistant epithelial ovarian cancer (EOC) cells to their chemosensitive counterparts and determine their impact on angiogenesis...
April 26, 2016: Reproductive Sciences
https://www.readbyqxmd.com/read/27091034/tissue-permeability-effects-associated-with-the-use-of-mucoadhesive-cationic-nanoformulations-of-docetaxel-in-the-bladder
#19
Rakhi Pandey, John K Jackson, Clement Mugabe, Richard Liggins, Helen M Burt
PURPOSE: Recently, efficacy studies in mice have shown that amine-terminated cationic (CNP) nanoparticulate carriers of DTX offer an improved formulation of the drug for intravesical delivery. It is hypothesized that this improved efficacy may arise from a carrier mediated bladder exfoliation process that removes the urothelial barrier allowing for increased drug uptake into bladder tissue. The objective of this study was to investigate exfoliation processes in fresh pig's bladders (ex vivo) exposed to three cationic polyglycerols with increasing degrees of amination (denoted 350, 580 and 780)...
August 2016: Pharmaceutical Research
https://www.readbyqxmd.com/read/27042223/safety-and-efficacy-of-single-agent-docetaxel-taxotere-administered-weekly-in-non-small-cell-lung-carcinoma-patients-in-korea-an-observational-study
#20
Sun Min Lim, Byeong Bae Park, Keun-Chil Park, Hoon-Kyo Kim, Jong Seok Lee, Sung Hwa Bae, Seung-Sei Lee, Jin-Hyoung Kang, Se-Hoon Park, Gyeong-Won Lee, Hyo-Rac Lee, Jae Hong Seo, Yong Tae Kim, Sung Hyun Yang, Joo-Hang Kim
BACKGROUND: To investigate the efficacy, safety, and tolerability of weekly docetaxel treatment in advanced non-small cell lung cancer (NSCLC) patients in Korea. METHODS: This prospective observational study included Korean advanced NSCLC patients with Eastern Cooperative Oncology Group performance status <2 who received weekly monotherapy of docetaxel at a dose determined by the physician. Efficacy measurements included tumor response rate, overall survival (OS), progression-free survival, and one-year survival rate...
March 2016: Thoracic Cancer
keyword
keyword
104013
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"